Trial Profile
Clinical study of selegiline hydrochloride (FP OD tablet 2.5) to flexion of spine in Parkinson's disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2015
Price :
$35
*
At a glance
- Drugs Selegiline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 22 Sep 2015 Status changed from active, no longer recruiting to completed, according to University Hospital Medical Information Network - Japan record.
- 15 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 19 Jan 2014 According to University Hospital Medical Information Network - Japan record, Planned End Date changed from 19 Jul 2013 to 19 Dec 2014.